Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
No edit summary
Line 739: Line 739:
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|
|
|
|
|
Line 748: Line 748:
|
|
|
|
|
|Tracy Tucker, PhD, FCCMG
|
|
|
|
Line 755: Line 755:
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|Mixed-phenotype acute leukaemia with KMT2A rearrangement
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|
|
|
|
|
Line 764: Line 764:
|
|
|
|
|
|Tracy Tucker, PhD, FCCMG
|
|
|
|
Line 787: Line 787:
|Mixed-phenotype acute leukaemia, B/myeloid
|Mixed-phenotype acute leukaemia, B/myeloid
|Disease
|Disease
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|
|
|
|
|
Line 796: Line 796:
|
|
|
|
|
|Priyatharsini Nirmalanantham, MD and  Shashi Shetty, PhD
|
|
|
|
Line 803: Line 803:
|Mixed-phenotype acute leukaemia, T/myeloid
|Mixed-phenotype acute leukaemia, T/myeloid
|Disease
|Disease
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|
|
|
|
|
Line 812: Line 812:
|
|
|
|
|
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|
|
|
|
Line 819: Line 819:
|Mixed-phenotype acute leukaemia, rare types
|Mixed-phenotype acute leukaemia, rare types
|Disease
|Disease
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|
|
|
|
Line 828: Line 828:
|
|
|
|
|
|Elicia Goodale, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|
|
|
Line 851: Line 851:
|Acute undifferentiated leukaemia
|Acute undifferentiated leukaemia
|Disease
|Disease
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|
|
|
|
|
Line 860: Line 860:
|
|
|
|
|
|Amelia Nakanishi, MD and Shashi Shetty, PhD
|
|
|
|
Line 901: Line 901:
|Blastic plasmacytoid dendritic cell neoplasm
|Blastic plasmacytoid dendritic cell neoplasm
|Disease
|Disease
|Hao Liu, MD and Daynna J. Wolff, PhD
|
|
|
|
|
Line 910: Line 910:
|
|
|
|
|
|Hao Liu, MD and Daynna J. Wolff, PhD
|
|
|
|
Line 917: Line 917:
|Langerhans cell histiocytosis
|Langerhans cell histiocytosis
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
|
|
|
Line 926: Line 926:
|
|
|
|
|
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
|
|
Line 933: Line 933:
|Langerhans cell sarcoma
|Langerhans cell sarcoma
|Disease
|Disease
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
|
|
|
Line 942: Line 942:
|
|
|
|
|
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|
|
|
|
Line 1,045: Line 1,045:
|Histiocytic sarcoma
|Histiocytic sarcoma
|Disease
|Disease
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|
|
|
|
|
Line 1,054: Line 1,054:
|
|
|
|
|
|Marie-France Gagnon, MD, Mayo Clinic, Xinjie Xu, PhD FACMG, Mayo Clinic
|
|
|
|
Line 1,073: Line 1,073:
|
|
|
|
----<br />
|
|
|
|
Line 1,143: Line 1,144:
|KSHV/HHV8-associated multicentric Castleman disease
|KSHV/HHV8-associated multicentric Castleman disease
|Disease
|Disease
|Sudha Arumugam, MD
|
|
|
|
|
Line 1,152: Line 1,153:
|
|
|
|
|
|Sudha Arumugam, MD
|
|
|
|
Line 1,175: Line 1,176:
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
|
Line 1,184: Line 1,185:
|
|
|
|
|
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
Line 1,191: Line 1,192:
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|B-lymphoblastic leukaemia/lymphoma with hypodiploidy
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|
|
|
|
|
Line 1,200: Line 1,201:
|
|
|
|
|
|Ashwini Yenamandra PhD FACMG  Lisa Smith PhD FACMG  Yassmine Akkari PhD FACMG
|
|
|
|
Line 1,207: Line 1,208:
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|Disease
|Disease
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|
|
|
|
|
Line 1,216: Line 1,217:
|
|
|
|
|
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|
|
|
|
Line 1,223: Line 1,224:
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion
|Disease
|Disease
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
|
Line 1,232: Line 1,233:
|
|
|
|
|
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|
|
|
Line 1,239: Line 1,240:
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features
|Disease
|Disease
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|
|
|
|
|
Line 1,248: Line 1,249:
|
|
|
|
|
|Mark G. Evans, MD, University of California, Irvine  Fabiola Quintero-Rivera, MD, University of California, Irvine
|
|
|
|
Line 1,255: Line 1,256:
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement
|Disease
|Disease
|Yassmine Akkari  Nicolas Millan
|
|
|
|
|
Line 1,264: Line 1,265:
|
|
|
|
|
|Yassmine Akkari  Nicolas Millan
|
|
|
|
Line 1,271: Line 1,272:
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Disease
|Disease
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|
|
|
|
|
Line 1,280: Line 1,281:
|
|
|
|
|
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG  Cancer Category/Type    B-Lymphoblastic Leukemia/Lymphoma
|
|
|
|
Line 1,303: Line 1,304:
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|Disease
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|
Line 1,312: Line 1,313:
|
|
|
|
|
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
Line 1,319: Line 1,320:
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion
|Disease
|Disease
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
|
Line 1,328: Line 1,329:
|
|
|
|
|
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN  Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|
|
|
Line 1,392: Line 1,393:
|
|
|
|
|
|ISSUE - FIX
|
|
|
|
Line 1,405: Line 1,406:
|
|
|-
|-
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease||Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD|| || || || ||SG|| ||
|Chronic lymphocytic leukaemia/small lymphocytic lymphoma||Disease|| || || || || ||SG|| ||
|
|
|
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|
|
|
|
|
|
|-
|-
|Hairy cell leukaemia||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Hairy cell leukaemia||Disease|| || || || || ||SG|| ||
|
|
|
|*Snehal Patel, MD, PhD
|
|
|
|
|
|
|-
|-
|Splenic marginal zone lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Splenic marginal zone lymphoma||Disease|| || || || || ||SG|| ||
|
|
|
|*Snehal Patel, MD, PhD
|
|
|
|
|
|
|-
|-
|Splenic diffuse red pulp small B-cell lymphoma||Disease||*Snehal Patel, MD, PhD|| || || || ||SG|| ||
|Splenic diffuse red pulp small B-cell lymphoma||Disease|| || || || || ||SG|| ||
|
|
|
|*Snehal Patel, MD, PhD
|
|
|
|
Line 1,435: Line 1,436:
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|Splenic B-cell lymphoma/leukaemia with prominent nucleoli
|Disease
|Disease
|*Snehal Patel, MD, PhD
|
|
|
|
|
Line 1,444: Line 1,445:
|
|
|
|
|
|*Snehal Patel, MD, PhD
|
|
|
|
Line 1,451: Line 1,452:
|Lymphoplasmacytic lymphoma
|Lymphoplasmacytic lymphoma
|Disease
|Disease
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|
|
|
|
|
Line 1,460: Line 1,461:
|
|
|
|
|
|Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and *Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|
|
|
|
Line 1,499: Line 1,500:
|Nodal marginal zone lymphoma
|Nodal marginal zone lymphoma
|Disease
|Disease
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|
|
|
|
|
Line 1,508: Line 1,509:
|
|
|
|
|
|Andrew Ly, DO and Shivani Golem, PhD, FACMG
|
|
|
|
Line 1,515: Line 1,516:
|Paediatric nodal marginal zone lymphoma
|Paediatric nodal marginal zone lymphoma
|Disease
|Disease
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
|
|
|
|
Line 1,524: Line 1,525:
|
|
|
|
|
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|
|
|
|
Line 1,531: Line 1,532:
|In situ follicular B-cell neoplasm
|In situ follicular B-cell neoplasm
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|
|
Line 1,540: Line 1,541:
|
|
|
|
|
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|
Line 1,547: Line 1,548:
|Follicular lymphoma
|Follicular lymphoma
|Disease
|Disease
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
|
|
|
|
Line 1,556: Line 1,557:
|
|
|
|
|
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
|
|
|
Line 1,563: Line 1,564:
|Paediatric-type follicular lymphoma
|Paediatric-type follicular lymphoma
|Disease
|Disease
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|
|
|
|
|
Line 1,572: Line 1,573:
|
|
|
|
|
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|
|
|
|
Line 1,595: Line 1,596:
|Primary cutaneous follicle centre lymphoma
|Primary cutaneous follicle centre lymphoma
|Disease
|Disease
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
|
|
|
Line 1,604: Line 1,605:
|
|
|
|
|
|Linlin Gao, MD, PhD and Shivani Golem, PhD, FACMG
|
|
|
|
Line 1,611: Line 1,612:
|In situ mantle cell neoplasm
|In situ mantle cell neoplasm
|Disease
|Disease
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
|
|
|
Line 1,620: Line 1,621:
|
|
|
|
|
|Rina Kansal, MD; Versiti Blood Center of Wisconsin
|
|
|
|
Line 1,627: Line 1,628:
|Mantle cell lymphoma
|Mantle cell lymphoma
|Disease
|Disease
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|
Line 1,636: Line 1,637:
|
|
|
|
|
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
Line 1,643: Line 1,644:
|Leukaemic non-nodal mantle cell lymphoma
|Leukaemic non-nodal mantle cell lymphoma
|Disease
|Disease
|<br />
|
|
|
|
|
Line 1,652: Line 1,653:
|
|
|
|
|
|<br />
|
|
|
|
Line 1,673: Line 1,674:
|
|
|-
|-
|Diffuse large B-cell lymphoma, NOS||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|Diffuse large B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
|
|
|
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|
|
|
|
Line 1,687: Line 1,688:
|
|
|-
|-
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements||Disease|| || || || || ||GC|| ||
|
|
|
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|
|
|
|
|
|
|-
|-
|ALK-positive large B-cell lymphoma||Disease||Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)|| || || || ||GC|| ||
|ALK-positive large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|
|
|
|
|
|
|-
|-
|Large B-cell lymphoma with IRF4 rearrangement||Disease||*Afia Hasnain, MBBS, PhD|| || || || ||GC|| ||
|Large B-cell lymphoma with IRF4 rearrangement||Disease|| || || || || ||GC|| ||
|
|
|
|*Afia Hasnain, MBBS, PhD
|
|
|
|
|
|
|-
|-
|High grade B-cell lymphoma with 11q aberrations||Disease||Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina|| || || || ||GC|| ||
|High grade B-cell lymphoma with 11q aberrations||Disease|| || || || || ||GC|| ||
|
|
|
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|
|
|
|
Line 1,750: Line 1,751:
|
|
|-
|-
|Plasmablastic lymphoma||Disease||Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)|| || || || ||GC|| ||
|Plasmablastic lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|
|
|
|
|
|
|-
|-
|Primary large B-cell lymphoma of immune-privileged sites||Disease||Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center|| || || || ||GC|| ||
|Primary large B-cell lymphoma of immune-privileged sites||Disease|| || || || || ||GC|| ||
|
|
|
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|
|
|
|
Line 1,771: Line 1,772:
|
|
|-
|-
|Intravascular large B-cell lymphoma||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland|| || || || ||GC|| ||
|Intravascular large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|
|
|
|
Line 1,792: Line 1,793:
|
|
|-
|-
|High-grade B-cell lymphoma, NOS||Disease||Aiko Otsubo, PhD, Indiana University|| || || || ||GC|| ||
|High-grade B-cell lymphoma, NOS||Disease|| || || || || ||GC|| ||
|
|
|
|Aiko Otsubo, PhD, Indiana University
|
|
|
|
|
|
|-
|-
|Burkitt lymphoma||Disease||Becky Leung, MBBS (Hons), BSc, Pathology Queensland|| || || || ||GC|| ||
|Burkitt lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|
|
|
|
Line 1,834: Line 1,835:
|
|
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)|| || || || ||GC|| ||
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease|| || || || || ||GC|| ||
|
|
|
|Anna Shestakova, MD, PhD, Fellow, University of Utah/ARUP Laboratories  Fabiola Quintero-Rivera, MD, Professor, University of California Irvine (UCI)
|
|
|
|
Line 1,862: Line 1,863:
|
|
|-
|-
|Classic Hodgkin lymphoma||Disease||Patricia V. Hernandez, M.D., Washington University School of Medicine|| || || || ||GC|| ||
|Classic Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|
|
|
|Patricia V. Hernandez, M.D., Washington University School of Medicine
|
|
|
|
Line 1,914: Line 1,915:
|
|
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease||Heather E. Williams, PhD, MS, PgD, ErCLG|| || || || ||SG
|Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|Heather E. Williams, PhD, MS, PgD, ErCLG
|
|
|
|
|
|
|-
|-
|Monoclonal immunoglobulin deposition disease||Disease||Chen Yang, MD, PhD, University of Michigan|| || || || ||SG
|Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|Chen Yang, MD, PhD, University of Michigan
|
|
|
|
Line 1,938: Line 1,939:
|
|
|-
|-
|Gamma heavy chain disease||Disease||Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA|| || || || ||SG
|Gamma heavy chain disease||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|Manisha Brahmbhatt-Sutariya  Asst. Professor, Dept. of Pathology and Human Anatomy  Technical Supervisor, Clinical Genetics Laboratory  Loma Linda University, Medical Center, CA
|
|
|
|
Line 1,962: Line 1,963:
|
|
|-
|-
|Plasma cell myeloma / multiple myeloma||Disease||*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas|| || || || ||SG
|Plasma cell myeloma / multiple myeloma||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|*Huan Mo, MD, MS *Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|
|
|
|
|
|
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD|| || || || ||SG
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || || ||SG
| ||
| ||
|
|
|
|Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|
|
|
|
Line 2,027: Line 2,028:
|Early T-precursor lymphoblastic leukaemia / lymphoma
|Early T-precursor lymphoblastic leukaemia / lymphoma
|Disease
|Disease
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
|
Line 2,036: Line 2,037:
|
|
|
|
|
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
Line 2,057: Line 2,058:
|
|
|-
|-
|T-large granular lymphocytic leukaemia||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
|
|
|
|*Michelle Don, MD, MS
|
|
|
|
|
|
|-
|-
|NK-large granular lymphocytic leukaemia||Disease||Michelle Don, MD|| || || || ||SK|| ||
|NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
|
|
|
|Michelle Don, MD
|
|
|
|
|
|
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center|| || || || ||SK|| ||
|Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|
|
|
|
|
|
|-
|-
|Sezary syndrome||Disease||Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina|| || || || ||SK|| ||
|Sezary syndrome||Disease|| || || || || ||SK|| ||
|
|
|
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|
|
|
|
|
|
|-
|-
|Aggressive NK-cell leukaemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| ||
|
|
|
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|
|
|
|
Line 2,106: Line 2,107:
|
|
|-
|-
|Mycosis fungoides||Disease||Jane Scribner, MD and Daynna J. Wolff, PhD|| || || || ||SK|| ||
|Mycosis fungoides||Disease|| || || || || ||SK|| ||
|
|
|
|Jane Scribner, MD and Daynna J. Wolff, PhD
|
|
|
|
Line 2,120: Line 2,121:
|
|
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD|| || || || ||SK|| ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|
|
|
|
Line 2,155: Line 2,156:
|
|
|-
|-
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|
|
|
|
Line 2,169: Line 2,170:
|
|
|-
|-
|Enteropathy-associated T-cell lymphoma||Disease||*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD|| || || || ||SK|| ||
|Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|
|
|
|
|
|
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD|| || || || ||SK|| ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|
|
|
|
|
|
|-
|-
|Intestinal T-cell lymphoma, NOS||Disease||Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)|| || || || ||SK|| ||
|Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|
|
|
|
|
|
|-
|-
|Hepatosplenic T-cell lymphoma||Disease||*Michelle Don, MD, MS|| || || || ||SK|| ||
|Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|*Michelle Don, MD, MS
|
|
|
|
Line 2,204: Line 2,205:
|
|
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease||Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA|| || || || ||SK|| ||
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|
|
|
|
|
|
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center|| || || || ||SK|| ||
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|
|
|
|
|
|
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG|| || || || ||SK|| ||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| ||
|
|
|
|* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG
|
|
|
|
Line 2,232: Line 2,233:
|
|
|-
|-
|Nodal TFH cell lymphoma, NOS||Disease||Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD|| || || || ||SK|| ||
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|
|
|
|
Line 2,281: Line 2,282:
|
|
|-
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease||*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA|| || || || ||SK|| ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
|
|
|
|*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA
|
|
|
|
Line 2,308: Line 2,309:
|Follicular dendritic cell sarcoma
|Follicular dendritic cell sarcoma
|Disease
|Disease
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|
|
Line 2,317: Line 2,318:
|
|
|
|
|
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"